3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA, GA
Market cap: $121.4M (2/10/2026)
Price: $1.71
Inhibikase Therapeutics Files $185 Million Prospectus Supplement for ATM Program
Inhibikase Therapeutics Enters Underwriting Agreement for Public Offering
Investor Presentation
Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
Submission of Matters to a Vote of Security Holders
Announces First Quarter 2025 Financial Results and Highlights Recent Activity — Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension
Annual Report to Security Holders
Q3
Q2
Q1
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Initial Statement of Beneficial Ownership
Schedule 14F-1 Information Statement